A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.
Josep TaberneroEric Van CutsemElena GarraldaDavid TaiFilippo G De BraudRavit GevaMark T J van BusselKatia Fiorella DottiElena ElezMaría J de MiguelKevin LitwilerDanielle MurphyMichelle EdwardsVan Karlyle MorrisPublished in: The oncologist (2023)
ClinicalTrials.gov, NCT02278133.